Related coverage linked through entity extraction aliases.
Feb 23, 2026
iRegene Therapeutics has dosed the first U.S. patient in a Phase IIa trial of NouvNeu001 for Parkinson's disease and enrolled the first patient in a China trial of NouvNeu004 for Multiple System Atrophy.
Feb 19, 2026
Serina Therapeutics has enrolled the first patient in its Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease in Australia, with dosing expected to begin in the first quarter of 2026.
Feb 18, 2026
BioArctic reported net revenues of SEK 184.0 M for Q4 2025, driven by Leqembi royalties and Novartis partnership income. Leqembi received multiple regulatory approvals and submissions across global markets during the quarter.
Feb 18, 2026
The global AI in biotechnology market was valued at USD 1,033 million in 2024 and is projected to reach USD 1,971 million by 2031, growing at a CAGR of 10.6%. A separate AI in precision medicine market is forecast to reach $38.88 billion by 2034 with a 35.5% CAGR.
Feb 17, 2026
Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation over early-stage programs. Oncology and CNS programs have emerged as strategic M&A targets due to large commercial markets and significant unmet medical needs.
Feb 17, 2026
Newron Pharmaceuticals has secured up to €38 million in milestone-based financing from European and Asian investors to advance its Phase III ENIGMA-TRS program evaluating evenamide as an add-on therapy for treatment-resistant schizophrenia.
Feb 14, 2026
Researchers demonstrate that a fully implanted brain device can detect walking states in Parkinson's patients during unsupervised daily activities, opening the door to adaptive deep brain stimulation therapies that adjust to real-world movement.
Dec 30, 2025
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
Feb 25, 2025
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
